Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.

Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U.

Nat Med. 2013 Apr;19(4):446-51. doi: 10.1038/nm.3102. Epub 2013 Mar 3.

PMID:
23455714
2.

Antidote reverses anticoagulant effects of factor Xa inhibitors in minutes, studies show.

Mayor S.

BMJ. 2015 Nov 12;351:h6086. doi: 10.1136/bmj.h6086. No abstract available.

PMID:
26567177
3.

Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.

Fukuda T, Kamisato C, Honda Y, Matsushita T, Kojima T, Furugohri T, Morishima Y, Shibano T.

Thromb Res. 2013 Jun;131(6):540-6. doi: 10.1016/j.thromres.2013.04.016. Epub 2013 May 11.

PMID:
23673387
4.

Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.

Bianchini EP, Fazavana J, Picard V, Borgel D.

Blood. 2011 Feb 10;117(6):2054-60. doi: 10.1182/blood-2010-06-288522. Epub 2010 Nov 3.

5.

Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.

Kawamura M, Konishi N, Hiroe K, Shofuda K, Imaeda Y, Fujimoto T, Kubo K.

J Cardiovasc Pharmacol. 2010 Aug;56(2):156-61. doi: 10.1097/FJC.0b013e3181e2bfcf. Erratum in: J Cardiovasc Pharmacol. 2010 Oct;56(4):439.

PMID:
20410831
6.

In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S.

Thromb Res. 2012 Apr;129(4):e77-82. doi: 10.1016/j.thromres.2011.07.026. Epub 2011 Aug 17.

PMID:
21851967
8.

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.

Barrett YC, Wang Z, Frost C, Shenker A.

Thromb Haemost. 2010 Dec;104(6):1263-71. doi: 10.1160/TH10-05-0328. Epub 2010 Oct 26.

PMID:
20978714
9.

Reversal of anticoagulants: an overview of current developments.

Greinacher A, Thiele T, Selleng K.

Thromb Haemost. 2015 May;113(5):931-42. doi: 10.1160/TH14-11-0982. Epub 2015 Apr 2. Review.

PMID:
25832311
10.

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.

Wong PC, Crain EJ, Watson CA, Xin B.

J Thromb Haemost. 2009 Aug;7(8):1313-20. doi: 10.1111/j.1538-7836.2009.03503.x. Epub 2009 Jun 3.

11.

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M.

Circulation. 2011 Oct 4;124(14):1573-9. doi: 10.1161/CIRCULATIONAHA.111.029017. Epub 2011 Sep 6.

12.

Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.

Sinha U, Ku P, Malinowski J, Zhu BY, Scarborough RM, Marlowe CK, Wong PW, Lin PH, Hollenbach SJ.

Eur J Pharmacol. 2000 Apr 21;395(1):51-9.

PMID:
10781674
14.

Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin.

Chan S, Kong M, Minning DM, Hedner U, Marder VJ.

J Thromb Haemost. 2003 Apr;1(4):760-5.

15.

Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications.

Harder S, Parisius J, Picard-Willems B.

Thromb Res. 2008;123(2):396-403. doi: 10.1016/j.thromres.2008.05.010. Epub 2008 Jun 24.

PMID:
18571698
16.

Factor Xa inhibitors--new anticoagulants for secondary haemostasis.

Perzborn E.

Hamostaseologie. 2009 Aug;29(3):260-7.

PMID:
19644596
17.

A role for coagulation factor Xa in experimental pulmonary arterial hypertension.

Delbeck M, Nickel KF, Perzborn E, Ellinghaus P, Strassburger J, Kast R, Laux V, Schäfer S, Schermuly RT, von Degenfeld G.

Cardiovasc Res. 2011 Oct 1;92(1):159-68. doi: 10.1093/cvr/cvr168. Epub 2011 Jun 15.

18.

Clinical pharmacology of direct and indirect factor Xa inhibitors.

Rupprecht HJ, Blank R.

Drugs. 2010 Nov 12;70(16):2153-70. doi: 10.2165/11538030-000000000-00000. Review.

PMID:
20964458
19.

Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects.

Yates S, Sarode R.

Curr Opin Hematol. 2013 Nov;20(6):552-7. doi: 10.1097/MOH.0b013e328365a164. Review.

PMID:
24104417
20.

Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.

Biemond BJ, Perzborn E, Friederich PW, Levi M, Buetehorn U, Büller HR.

Thromb Haemost. 2007 Mar;97(3):471-7.

PMID:
17334516
Items per page

Supplemental Content

Write to the Help Desk